Key result
Olmesartan suppressed progressive proteinuria in Zucker diabetic fatty rats by approximately 70% at a high dose and 30% at a low dose, retarding the progression of diabetic nephropathy.
Why the study?
Does olmesartan prevent the progression of nephropathy in an animal model of type 2 diabetes?
Does olmesartan prevent the progression of nephropathy in an animal model of type 2 diabetes?
p-value: p=<0.01
Olmesartan retards the progression of nephropathy associated with type 2 diabetes in an animal model, an effect that is at least partly independent of its antihypertensive properties.
No takes yet. Share an insight, caveat, or question.
Olmesartan may retard diabetic nephropathy in animal models; leaves open translation to human type 2 diabetes.
Mizuno et al. (2002) studied Type 2 diabetes with nephropathy (animal model) (n=40). Olmesartan medoxomil vs. Vehicle control was evaluated on Progressive proteinuria (p=<0.01). Olmesartan suppressed progressive proteinuria in Zucker diabetic fatty rats by approximately 70% at a high dose and 30% at a low dose, retarding the progression of diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: